Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
Jean A. Klastersky, Jean‐Paul Sculier, G. Bureau et al. · Journal of Clinical Oncology · 1989
We conducted a randomized study comparing the survival after treatment with cisplatin (120 mg/m2) or cisplatin plus etoposide (100 mg/m2 on days 1, 2, and 3) in 162 evaluable patients with advanced non-small-cell lung cancer (NSCLC). No statistically significant difference in survival was detected; the median survival was 26 and 22 weeks, respectively, for patients receiving cisplatin and for those receiving cisplatin plus etoposide. The objective response rate was 19% for cisplatin and 26% for the combination; the corresponding response rates were 17% and 43% in patients with limited disease. No significant differences were detected between the two study arms as far as toxicity was concerned, except for alopecia and granulocytopenia, which occurred more frequently in patients treated with cisplatin plus etoposide.
Cited by 130 works. doi:10.1200/jco.1989.7.8.1087
Authors
- Jean A. Klastersky
- Jean‐Paul Sculier
- G. Bureau
- P Libert
- Paul Ravez
- G. Vandermoten
- Jacques Thiriaux
- J. Lecomte
- R Cordier
- G Dabouis
References
- Nonparametric Estimation from Incomplete Observations
- Regression Models and Life-Tables
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
- Planning the size and duration of a clinical trial studying the time to some critical event
- An Improved Approximate Formula for Calculating Sample Sizes for Comparing Two Binomial Distributions
- Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules
- cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
- Commentary: current status of chemotherapy for non-small cell lung cancer.
- Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium)
- Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.